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More than 100 prominent oncologists from across the United States have called on cancer 
patients to challenge the high prices charged by pharmaceutical companies for new cancer 
drugs. They claim drug companies, insurance companies, some patient advocacy groups and 
many hospitals and physicians are too financially conflicted to be driving the debate. 
Their call is motivated by the astronomical prices charged for some new cancer drugs. And 
Australia is in the same boat. Earlier this year, for instance, the Therapeutic Goods 
Administration started subsidising pembrolizumab (Keytruda) for the treatment of patients 
with advanced melanoma. The drug is expected to cost A$150,000 per patient for each year 
of treatment, which is almost twice the national average annual income. 
Unlike in the United States, where patients' insurance covers the costs, the Australian 
taxpayer subsidises drugs listed on the Pharmaceutical Benefits Scheme (PBS). In cases 
where new drugs are not subsidised, they’re paid for directly by patients, or by state-funded 
hospitals (often after approval by drug committees). They can also be provided free or 
subsidised by pharmaceutical companies for “compassionate use”. 
Blurred by emotion 
Decisions to subsidise drugs and improve their accessibility should be based on an 
assessment of their value. In Australia, for instance, the Pharmaceutical Benefits Advisory 
Committee examines new drugs for effectiveness, safety and value for money compared to 
other treatments before recommending PBS listing – or not. 
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But the imperative to “save lives” or “beat cancer” — particularly where there’s vigorous 
public, professional and industry advocacy — can be so profound that it overwhelms the 
requirement that medicines should be efficacious and cost-effective. This tension between 
emotional and economic considerations frequently challenges and compromises public 
decision-making about the value of drugs. 
Consider the case of eribulin (Halaven), a drug for treating advanced breast cancer. The UK 
National Institute for Health and Clinical Excellence (NICE is the rough equivalent of PBAC 
although it has a broader role) considered the drug but rejected it as too expensive. 
Eribulin was subsequently covered by the UK Cancer Drugs Fund, a pool of public money 
allocated to pay for drugs not approved via the usual route. The price accepted by the fund 
was among the highest in Europe for the drug; the price rejected by NICE had been the 
lowest. 
Clearly, when standards of cost-effectiveness are reduced in the name of “improved access”, 
prices can rise arbitrarily. In most markets, supply and demand, competition and consumer 
choice curtail such arbitrary fluctuations in price. 
But the market for innovative cancer drugs doesn’t follow this pattern because prices can 
increase dramatically even in “growing” markets, without clear reasons. In 2013, for 
example, a group of experts in chronic myeloid leukemia described how the price of imatinib 
(Gleevec) increased three-fold over a decade. This happened even though all research and 
development costs were accounted for in the original price, and the number of people using 
the drug was dramatically increasing. Heightened demand alone cannot explain such an 
increase. 
What makes cancer drugs different 
Cancer drug markets clearly behave quite differently to what we might expect. There are 
three key reasons for this. 
First, governments are creating a “price deregulation eco-system” for cancer drugs by 
establishing special funds that challenge accepted standards of value, and by curtailing the 
ability of payers to negotiate prices. The UK government has the Cancer Drugs Fund 
discussed above, while US legislation limits the ability of Medicare – the US government’s 
health insurance program for people who are 65 and older and certain others – to negotiate 
drug prices. Laws in the latter country effectively force the health insurer to pay for cancer 
drugs used for a “medically accepted indication”, and prevent it from considering related 
cancer drugs as interchangeable. 
In other words, US Medicare cannot make the call about whether the drug is worth its asking 
price, or negotiate prices based on cheaper available alternatives. The fact that the US pays 
the most for many drugs — including many cancer drugs — should therefore be no surprise. 
And if other countries are paying high prices for drugs, it makes it easier to justify these high 
prices elsewhere. 
Second, there’s a lack of significant competition for many new cancer drugs. In an attempt to 
understand why South Korea paid so much less for drugs used to treat chronic myeloid 
leukemia — in some instances less than 20% of the US price — the same group of experts 
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mentioned previously noted the country had its own locally discovered drug for treating this 
disease. The price of competing products appeared to be based on this local drug’s price. 
The lack of competition in the cancer drugs market is exacerbated by the rise of new 
“biological agents”, which are more difficult to replicate than small-molecule drugs, and by 
industry practices aimed at extending the patent lives of existing products, thwarting generic 
competition. 
Finally, markets in health care, including for high-cost cancer drugs, are powerfully 
influenced by existential and moral considerations — specifically fear of death and disability, 
and desire for greater quantity and quality of life. Cancer patients, their families and the 
oncologists who care for them are often willing to try drugs in the hope they will work, 
regardless of the price or prospect of benefit, which is frequently quite limited in the case of 
new, expensive cancer therapies. And as long as there are people willing to pay high prices 
or, as is usually the case, to demand subsidised access to cancer drugs, there’s no reason for 
the industry to reduce its prices. 
Hope, fear and desperation, along with the unique characteristics of the cancer drug market, 
create a “perfect storm” that continues to drive up prices for cancer drugs. Unless we regain 
sight of the need to use regulatory incentives to reward only genuine innovation, and ensure 
that we receive sufficient value for the money we spend on new medicines, this upward trend 
for cancer drug prices is set to continue. 
The call by the US oncologists for patients to demand reductions in the price of the new 
drugs may be too much of an ask as these people have more to lose in this debate. It may also 
be too narrowly focused as it’s not just cancer patients but all of us who should demand the 
drugs we need at a price that our publicly funded health systems can afford. 
 
